Patents Assigned to ChemGenex Pharmaceuticals, Inc.
-
Publication number: 20120207855Abstract: A method of treatment of a host with a cellular proliferative disease, comprising contacting the host with a cephalotaxine and an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease, is described. In some embodiments, the cephalotaxine comprises homoharringtonine (cephalotaxine, 4-methyl-2-hydroxy-2-(4-hydroxy-4-methyl pentyl)butanediocate ester). Antiproliferative agents of the invention comprise alkylating agents, intercalating agents, metal coordination complexes, pyrimidine nucleosides, purine nucleosides, inhibitors of nucleic acid associated enzymes and proteins, and agents affecting structural proteins and cytoplasmic enzymes.Type: ApplicationFiled: December 23, 2011Publication date: August 16, 2012Applicant: ChemGenex Pharmaceuticals, Inc.Inventor: Dennis M. Brown
-
Publication number: 20110293676Abstract: The present disclosure provides oral dosage forms comprising a cephalotaxine and a pharmaceutically acceptable carrier selected from protein, carbohydrate and lipid, an oral dosage form comprising cephalotaxine and a second active agent, as well as methods of treating subjects with such oral formulations.Type: ApplicationFiled: August 11, 2011Publication date: December 1, 2011Applicant: ChemGenex Pharmaceuticals, Inc.Inventors: Dennis BROWN, Shawnya MICHAELS
-
Publication number: 20110262383Abstract: The present invention provides methods for dosing patients with naphthalimides, including amonafide, amonafide salts, and analogs thereof based on N-acetyl transferase genotyping. The invention also provides methods for dosing the amount of granulocyte colony stimulating factor (GCSF) used in combination with naphthalimide to prevent or modulate leukocytopenia.Type: ApplicationFiled: July 5, 2011Publication date: October 27, 2011Applicant: ChemGenex Pharmaceuticals, Inc.Inventor: Dennis M. Brown
-
Publication number: 20110008307Abstract: A method of treatment of a host with a cellular proliferative disease, comprising contacting the host with a cephalotaxine and an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease, is described. In some embodiments, the cephalotaxine comprises homoharringtonine (cephalotaxine, 4-methyl-2-hydroxy-2-(4-hydroxy-4-methyl pentyl)butanediocate ester). Antiproliferative agents of the invention comprise alkylating agents, intercalating agents, metal coordination complexes, pyrimidine nucleosides, purine nucleosides, inhibitors of nucleic acid associated enzymes and proteins, and agents affecting structural proteins and cytoplasmic enzymes.Type: ApplicationFiled: April 15, 2010Publication date: January 13, 2011Applicant: ChemGenex Pharmaceuticals, Inc.Inventor: Dennis M. BROWN
-
Publication number: 20110003742Abstract: The present invention provides methods for dosing patients with naphthalimides, including amonafide, amonafide salts, and analogs thereof based on N-acetyl transferase genotyping. The invention also provides methods for dosing the amount of granulocyte colony stimulating factor (GCSF) used in combination with naphthalimide to prevent or modulate leukocytopenia.Type: ApplicationFiled: March 9, 2010Publication date: January 6, 2011Applicant: ChemGenex Pharmaceuticals, Inc.Inventor: Dennis M. Brown
-
Patent number: 7842687Abstract: The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. This process comprises direct esterification of a natural cephalotaxine with an acylating compound constituted of a side chain precursor which backbone and functionalization are entirely preformed. The invention also concerns a natural, synthetic or semi-synthetic harringtonines including their tautomeric forms and their salts of the following formula: wherein n=2 (i.e. harringtonine) or n=3 (i.e. homoharringtonine), in which the total content of impurities, possibly including enantiomeric forms, is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97.5%.Type: GrantFiled: May 25, 2006Date of Patent: November 30, 2010Assignee: Chemgenex Pharmaceuticals, Inc.Inventors: Jean-Pierre Robin, Julie Blanchard, Jean-Pierre Marie, Nina Radosevic
-
Patent number: 7683050Abstract: The present invention is directed to compositions and methods for the treatment of patients with cephalotaxines, for example, homoharringtonine. The invention is also directed to improvements in the purity, manufacturing process, formulation and administration of homoharringtonine for the treatment of cancer and other aberrant cellular diseases. The invention also provides methods and compositions for antiparasitic, antifungal, antiviral and antibacterial treatments.Type: GrantFiled: August 1, 2006Date of Patent: March 23, 2010Assignee: Chemgenex Pharmaceuticals, Inc.Inventor: Dennis M. Brown
-
Patent number: 7642252Abstract: The invention relates to compositions and methods useful in treating or preventing angiogenic disease. The invention provides for compositions comprising cephalotaxine alkaloids as antiangiogenic agents for treatment of a host with an angiogenic disease or for prophylactic treatment of a host to inhibit the onset or progression of an angiogenic disease.Type: GrantFiled: July 22, 2003Date of Patent: January 5, 2010Assignee: Chemgenex Pharmaceuticals, Inc.Inventor: Dennis M. Brown
-
Publication number: 20090270368Abstract: The invention relates to compositions and methods useful in treating or preventing angiogenic disease. The invention provides for compositions comprising cephalotaxine alkaloids as antiangiogenic agents for treatment of a host with an angiogenic disease or for prophylactic treatment of a host to inhibit the onset or progression of an angiogenic disease.Type: ApplicationFiled: July 7, 2009Publication date: October 29, 2009Applicant: ChemGenex Pharmaceuticals, Inc.Inventor: Dennis M. BROWN
-
Publication number: 20090176759Abstract: A method for treating a leukemia patient that is resistant to a thymidine kinase inhibitor (TKI) other than imantinib comprising administering a cephalotaxine to said patient until said patient demonstrates a hematological or cytological response to said leukemia.Type: ApplicationFiled: December 8, 2008Publication date: July 9, 2009Applicant: ChemGenex Pharmaceuticals, Inc.Inventor: Dennis Brown
-
Publication number: 20090068236Abstract: The present disclosure provides oral dosage forms comprising a cephalotaxine and a pharmaceutically acceptable carrier selected from protein, carbohydrate and lipid, an oral dosage form comprising cephalotaxine and a second active agent, as well as methods of treating subjects with such oral formulations.Type: ApplicationFiled: April 14, 2008Publication date: March 12, 2009Applicant: ChemGenex Pharmaceuticals, Inc.Inventors: Dennis Brown, Shawnya Michaels
-
Patent number: 7135481Abstract: Methods of treating a solid tumor are disclosed comprising administering amonafide in combination with an antiproliferative agent.Type: GrantFiled: February 25, 2005Date of Patent: November 14, 2006Assignee: ChemGenex Pharmaceuticals, Inc.Inventor: Dennis M. Brown